Original research

Anterior circulation location-specific results for stent-assisted coiling – carotid versus distal aneurysms: 1-year outcomes from the Neuroform Atlas Stent Pivotal Trial

Ricardo A Hanel,1,2 Gustavo M Cortez,1 Brian T Jankowitz,2 Eric Sauvageau,1 Amin Aghaebrahim,1,3 Eugene Lin,3 Ashutosh P Jadhav,4,5 Bradley Gross,6 Ahmad Khaldi,7 Rishi Gupta,7 Donald Frei,8 David Loy,8 Lori Lyn Price,9 Steven W Hetts,9,10 Osama O Zaidat,1,3 ATLAS Investigators

ABSTRACT

Background The Neuroform Atlas Stent System is an established treatment modality for unruptured anterior and posterior circulation intracranial aneurysms. Location-specific results are needed to guide treatment decision-making. However, it is unclear whether there are differences in safety and efficacy outcomes between carotid and more distal anterior circulation aneurysms.

Methods The ATLAS IDE trial was a prospective, multicenter, single-arm, open-label interventional study that evaluated the safety and efficacy of the Neuroform Atlas Stent System. We compared differences in efficacy and safety outcomes of proximal internal carotid artery (ICA) versus distal and bifurcation anterior circulation aneurysms.

Results Of 182 cases, there were 70 aneurysms in the ICA and 112 in the distal anterior circulation (including ICA terminus/bifurcation). There were no significant differences in the primary efficacy endpoint (85.5% vs 83.9%, p=0.78) and complete aneurysm occlusion rates (88.7% vs 87.9%, p=0.78) between proximal ICA aneurysms and distal aneurysms, respectively. Complications were more often encountered in distal and bifurcation aneurysms, but the overall rate of major safety events was low and comparable between the two groups (1.4% vs 6.3%, p=0.14). Recanalization and retreatment rates were also similar between the groups.

Conclusion The results of this study suggest that the Neuroform Atlas Stent System is a safe and efficacious treatment modality for unruptured anterior circulation intracranial aneurysms, regardless of aneurysm location.

Trial registration number NCT02340585.

INTRODUCTION

Stent-assisted coiling (SAC) has emerged as a strategy for treating wide-neck and complex intracranial aneurysms. The scaffolding provided by the stent mesh has allowed the treatment of lesions previously not amenable to coiling alone. Further evidence suggests that the mesh structure facilitates the achievement of higher coil packing density and stability, along with stimulating re-endothelialization.1 The stent technology has been refined over the years, with multiple iterations designed to improve performance and outcomes.2

The Neuroform Atlas Stent System (Stryker Neurovascular, Fremont, CA, USA) is a newer generation of the Neuroform stent featuring a self-expanding, hybrid cell design. It was manufactured to improve navigability, device apposition, and conformability to the vessel wall. The system was initially approved under Humanitarian Device Exemption (HDE) in 2017, and full approval by the Food and Drug Administration (FDA) was granted in 2019. The Pivotal Trial of the Neuroform Atlas Stent for treatment of Anterior Circulation
Aneurysms (ATLAS IDE trial) formally investigated the safety and efficacy of the Atlas device for anterior circulation intracranial aneurysms. One-year findings indicated a primary efficacy rate of 84.7% and a 12-month adjusted major complication rate (major ipsilateral stroke or neurological death) of 4.4%, meeting both the primary and secondary performance goals. Similar results were reported by the Multi-centric European post-market follow-up study of the Neuroform Atlas Stent System (ATLAS EU PMCF study), with a complete occlusion rate at 1-year follow-up of 91.3%. The study also reported 4.9% major complication rate, with only 1% resulting in permanent morbidity or mortality.

Aneurysm location, along with vasculature morphology, may impact the outcome of endovascular stenting. The hemodynamics of sidewall aneurysms can differ from aneurysms in which sharp angulation between the parent vessel and aneurysm ostium exists. The deployment of a stent in bifurcation aneurysms can significantly modify local vasculature architecture and affect the stability of the aneurysmal neck.

**METHODS**

**Patients and study design**

The ATLAS IDE trial was a prospective, multicenter, single-arm, open-label interventional trial designed to demonstrate the safety and effectiveness of the next-generation Neuroform Atlas Stent System with any approved embolic coils on the market for the treatment of intracranial aneurysms. Eligible patients: (1) aged between 18 and 80 years; (2) documented wide-neck (neck ≥4 mm or dome-to-neck ratio of <2), saccular, intracranial aneurysm located within the anterior circulation (excluding the petrous internal carotid artery (ICA) to the superior hypophyseal ICA region); and (3) parent vessel with a diameter of ≥2 mm and ≤4.5 mm, which could be treated with bare metal coils. Main exclusion criteria included the presence of multiple untreated intracranial aneurysms, an acutely ruptured aneurysm (within 14 days of enrollment), prior aneurysm treatment, and an aneurysm with untreated parent vessel stenosis (>50%) at the target location, and no neurological death. Raymond–Roy occlusion classification was used to adjudicate the primary effectiveness outcome. Digital subtractions were performed on request, and details are otherwise available in the Pivotal Trial of the Neuroform Atlas Stent for Treatment of Anterior Circulation Aneurysms: One-Year Outcomes publication.

**Device and procedure**

The Neuroform Atlas is a self-expanding, open-cell, nitinol stent designed to provide support for the coil mass within the aneurysm and minimize stent deflection. Protocol required dual antiplatelet administration of aspirin (81–325 mg/day) and clopidogrel (75 mg/day) for at least 5 days prior to the procedure. Assessment of antiplatelet activity was not required per protocol, and all procedures were carried out under general anesthesia. Placement of a single device was preferably recommended, but a second device was allowed if judged necessary to improve wall apposition and adequately cover the aneurysm neck.

**Efficacy outcomes**

The primary efficacy outcome of the study was to compare the rate of complete aneurysm occlusion (100% occlusion) at 12-month angiographic follow-up between proximal versus distal anterior circulation aneurysms, in the absence of retreatment or parent vessel stenosis (>50%) at the target location, and no neurological death. Raymond–Roy occlusion classification was used to adjudicate the primary effectiveness outcome. Digital subtraction angiography was mandatory at 1-year follow-up to assess efficacy outcomes, and all radiological images were reviewed and adjudicated by an independent imaging core lab. Secondary efficacy outcomes included differences in the incidence of target aneurysm retreatment and rates of aneurysm recanalization.

### Table 1 Baseline and procedural characteristics

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Proximal (ICA group)</th>
<th>Distal (non-ICA group)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Demographics</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age (years), mean (SD)</td>
<td>56.7 (11.0)</td>
<td>62.1 (11.3)</td>
<td>0.03</td>
</tr>
<tr>
<td>Male, n (%)</td>
<td>10 (14.3)</td>
<td>39 (34.8)</td>
<td>0.006</td>
</tr>
<tr>
<td>White, n (%)</td>
<td>55 (78.6)</td>
<td>92 (82.1)</td>
<td>0.44</td>
</tr>
<tr>
<td>Aneurysm characteristics, mean (SD)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aneurysm neck width (mm)</td>
<td>4.0 (1.1)</td>
<td>4.2 (1.3)</td>
<td>0.27</td>
</tr>
<tr>
<td>Aneurysm size (mm)</td>
<td>0 (2.0)</td>
<td>6.2 (2.3)</td>
<td>0.35</td>
</tr>
<tr>
<td>Dome-to-neck ratio</td>
<td>1.2 (0.3)</td>
<td>1.1 (0.3)</td>
<td>0.25</td>
</tr>
<tr>
<td>Parent vessel diameter proximal to the aneurysm neck (mm)</td>
<td>3.7 (0.5)</td>
<td>2.6 (0.5)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Parent vessel diameter distal to the aneurysm neck (mm)</td>
<td>3.4 (0.5)</td>
<td>2.3 (0.4)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Previously ruptured aneurysm treatment, n (%)</td>
<td>6 (8.6)</td>
<td>16 (14.3)</td>
<td>0.23*</td>
</tr>
<tr>
<td>Coiling only</td>
<td>5 (83.3)</td>
<td>11 (66.8)</td>
<td></td>
</tr>
<tr>
<td>Balloon-assisted coiling</td>
<td>1 (16.7)</td>
<td>0 (0.0)</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>0 (0.0)</td>
<td>5 (31.2)</td>
<td></td>
</tr>
<tr>
<td>Procedural technical success, n (%)</td>
<td>70 (100.0)</td>
<td>112 (100.0)</td>
<td>N/A</td>
</tr>
<tr>
<td>Stents implanted, n (%)</td>
<td>0.07</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>66 (94.3)</td>
<td>87 (77.7)</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>4 (5.7)</td>
<td>25 (22.3)</td>
<td></td>
</tr>
<tr>
<td>Immediate Raymond Class (core lab), n (%)</td>
<td>0.26</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>52 (76.5)</td>
<td>88 (78.6)</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>14 (20.6)</td>
<td>14 (12.5)</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>2 (2.9)</td>
<td>10 (8.9)</td>
<td></td>
</tr>
<tr>
<td>Raymond Class 1 and 2 combined, n (%)</td>
<td>66 (97.1)</td>
<td>102 (91.1)</td>
<td>0.14</td>
</tr>
</tbody>
</table>

Values in bold type indicate statistical significance.

*Comparison of whether there was previous treatment, regardless of treatment modality.

N/A, not available.
Additionally, the occurrence of implant migration and the incidence of parent artery stenosis (>50%) were also evaluated.

**Safety outcomes**

The primary safety outcome was to compare the rate of major ipsilateral stroke (increase in National Institutes of Health Stroke Scale (NIHSS) score ≥4) or neurological death between proximal and distal aneurysms at 12-month follow-up. Secondary safety outcomes included worsening major ipsilateral stroke, rate of subarachnoid hemorrhage, and rate of target aneurysm rupture. A clinical events committee evaluated any serious device-related events and prespecified safety event endpoints.

**Statistical analyses**

Categorical data were summarized using frequencies and percentages, while continuous variables were presented as mean and SD. All analyses comparing location groups accounted for clustering within site. Generalized linear mixed models with a random effect were used for continuous variables and chi-square tests accounting for clustering were used for categorical variables. Analyses were performed using SAS version 9.4 (SAS Institute, Inc., Cary, NC, USA).

**RESULTS**

**Baseline and procedural characteristics**

Of the 201 participants enrolled in the study between June 2015 and October 2016, investigational device implantation was attempted in 182 patients (mITT cohort) who were included in the analysis. The mean age of the cohort was 60.3±11.4 years, mostly female (73.1%), and white (80.8%). Twenty-two (12.1%) patients had experienced a previous rupture of the targeted aneurysm and were previously treated with coiling (72.7%, 16/22), balloon-assisted coiling (4.5%, 1/22), or other means (22.7%). Of 182 patients, 153 had one stent implanted (84.1%) and 29 had two stents implanted (15.9%). A total of 70 (38.5%) patients composed the proximal group and 112 (61.5%) the distal aneurysm group. When comparing the groups (table 1), patients with distal aneurysms were more likely to be older, male, and have smaller vessel diameters. Figure 1 provides a visual representation of the enrollment process and details the aneurysm groups with the breakdown of aneurysm locations.

**Effectiveness outcomes**

Of 155 patients, composite effectiveness endpoint of complete aneurysm occlusion without clinically significant stenosis or retreatment and no neurological death was met by 85.5% and 83.9% of patients in the proximal and distal groups, respectively. When comparing angiographic follow-up availability at 1 year, the proportions were akin (88.6% for the proximal group vs 81.3% for the distal group, p=0.14). There were no statistically significant differences in the primary efficacy endpoint, Raymond–Roy aneurysm occlusion rates, recanalization rates, and incidence of parent artery stenosis between the groups. Patients from the distal group tended to have increased rates of worsening aneurysm occlusion (6.6% vs 3.2%) and retreatment (4.5% vs 2.9%) compared with the ICA group, but the differences were not statistically significant. Table 2 details the results of effectiveness outcomes between the groups.

**Safety outcomes**

When comparing proximal versus distal with respect to primary safety composite outcome, the non-ICA group tended to have a higher rate of events than the ICA group, although the difference was not statistically significant (6.3% vs 1.4%, p=0.14).
Hemorrhagic stroke

Table 2  Effectiveness outcomes

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Proximal (ICA group)</th>
<th>Distal (non-ICA group)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary efficacy endpoint, n (%)</td>
<td>53/62 (85.5)</td>
<td>78/93 (83.9)</td>
<td>0.78</td>
</tr>
<tr>
<td>Secondary efficacy endpoints</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Raymond Class (core lab), n (%)</td>
<td>1</td>
<td></td>
<td>0.78</td>
</tr>
<tr>
<td>1</td>
<td>55/62 (88.7)</td>
<td>80/91 (87.9)</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>48/62 (6.5)</td>
<td>8/91 (8.8)</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>3/62 (4.8)</td>
<td>3/91 (3.3)</td>
<td></td>
</tr>
<tr>
<td>Raymond Class 1 and 2 combined, n (%)</td>
<td>59/62 (95.2)</td>
<td>88/91 (96.7)</td>
<td>0.65</td>
</tr>
<tr>
<td>Recanalization, n (%)*</td>
<td>4/62 (6.5)</td>
<td>5/92 (5.4)</td>
<td>0.76</td>
</tr>
<tr>
<td>Progressive occlusion of target aneurysm (core lab), n (%)</td>
<td>0.61</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Same</td>
<td>37/62 (59.7)</td>
<td>55/91 (60.4)</td>
<td></td>
</tr>
<tr>
<td>Better</td>
<td>23/62 (37.1)</td>
<td>30/91 (33.0)</td>
<td></td>
</tr>
<tr>
<td>Worse</td>
<td>2/62 (3.2)</td>
<td>6/91 (6.6)</td>
<td></td>
</tr>
<tr>
<td>Parent artery stenosis &gt;50% (core lab), n (%)</td>
<td>1/62 (1.6)</td>
<td>1/91 (1.1)</td>
<td>0.78</td>
</tr>
<tr>
<td>Incidence of stent migration (core lab), n (%)</td>
<td>0/68 (0.0)</td>
<td>0/112 (0.0)</td>
<td>N/A</td>
</tr>
<tr>
<td>Incidence of retreatment (site-reported), n (%)‡</td>
<td>2/70 (2.9)</td>
<td>5/112 (4.5)</td>
<td>0.55</td>
</tr>
</tbody>
</table>

*Composite outcome: complete aneurysm occlusion (100% occlusion – Raymond Class 1) of the treated target lesion on 12-month angiography, in the absence of retreatment, or parent artery stenosis (>50%) at the target location, and no neurological death.
†Recanalization is defined as a Raymond score of 3 at 12-month visit or retreatment due to recanalization.
‡Two of the seven subjects had pre-planned staged procedures.
N/A, not available.

Similarly, a higher trend for subarachnoid hemorrhage and aneurysm rupture was encountered for the non-ICA group, but there were no significant differences between the groups. The results of safety outcome analyses in both groups are shown in table 3.

DISCUSSION

This is the first independently adjudicated study comparing differences in safety and efficacy outcomes of proximal versus distal anterior circulation aneurysms in patients undergoing SAC. The ATLAS IDE trial cohort included 70 (38.5%) ICA aneurysms and 112 (61.5%) distal anterior circulation aneurysms (including ICA terminus/bifurcation) successfully treated with the Neuroform Atlas Stent System. At 1-year follow-up, aneurysms treated with the Atlas device demonstrated high complete occlusion rates, with similar efficacy results in proximal and distal intracranial aneurysms. Patients from the non-ICA group had a trend for higher complications, but the difference in safety outcomes was not statistically significant.

Table 3  Safety endpoints

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Proximal (ICA group)</th>
<th>Distal (non-ICA group)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary safety endpoint, n (%)*</td>
<td>1/70 (1.4)</td>
<td>7/112 (6.3)</td>
<td></td>
</tr>
<tr>
<td>Secondary safety endpoints</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>New or worsening major ipsilateral stroke (CEC adjudicated), n (%)</td>
<td>1/70 (1.4)</td>
<td>7/112 (6.3)</td>
<td></td>
</tr>
<tr>
<td>Subarachnoid hemorrhage (CEC-adjudicated), n (%)</td>
<td>1/70 (1.4)</td>
<td>6/112 (5.4)</td>
<td></td>
</tr>
<tr>
<td>Aneurysm rupture (CEC-adjudicated), n (%)</td>
<td>1/70 (1.4)</td>
<td>4/112 (3.6)</td>
<td></td>
</tr>
</tbody>
</table>

*Any major ipsilateral stroke or neurological death within 12 months. Note that one subject experienced both major ipsilateral stroke and neurological death.
CEC, clinical events committee.

Stent-assisted techniques were initially conceptualized to treat wide-neck aneurysms by preventing coiling herniation into the parent vessel and achieving high packing density. Additional mechanisms contributing to high occlusion rates with SAC compared with coiling alone have been identified, including the mesh serving as a scaffold for neointima formation and changes in local flow dynamics. Tortuous vascular architecture can increase the risk of incomplete stent apposition, posing challenges to stent technology depending on the aneurysm’s location. The Atlas device is a self-expandable stent, allowing for better performance in curvatures and in cases of vessel size discrepancy between proximal and distal landing zones. Its hybrid design offers stability with closed cells at the proximal end, and open cells at the distal end provide conformability to the vessel wall. The laser-cut manufacturing also contributes to mitigating device foreshortening, providing an advantage compared with braided stents. These features, along with a low-profile mesh and a 0.0165 delivery system, have made the device an optimal tool for bifurcation and distal aneurysms treatment compared with other stents.

Local shear forces and spatial gradients at the apex of bifurcation aneurysms are highly dependent on the bifurcation and inflow vessel geometry and may contribute to the development of brain aneurysms. Conflicting results and hypotheses have been encountered over the years regarding the association and impact of vascular architecture and stent remodeling on bifurcation aneurysms. While the difference in complication rates between groups was not found to be statistically significant, there was a noticeable trend towards increased occurrences of stroke, vessel perforation, subarachnoid hemorrhage, and aneurysm rupture, which is easy to be rationalized by considering the more distal nature of the aneurysm, smaller vessel caliber, greater stress on vessel walls, larger ratio of microcatheter size to vessel size, among others.

Complete aneurysm occlusion in the non-ICA group was achieved by 87.9% of patients, and 4.5% underwent retreatment. Close to 90% of all anterior circulation aneurysms from the non-ICA group were located at bifurcations, with the anterior communicating artery (57%) and middle cerebral artery (24%) as the most common sites. Different endovascular modalities have been employed for the treatment of bifurcation aneurysms, including coiling, SAC, intrasaccular flow modifier, and flow diverters. The ATLAS IDE subanalysis of MCA aneurysms demonstrated higher rates of complete aneurysm occlusion (80.8%) compared with results from a meta-analysis of unruptured MCA aneurysms treated by different endovascular modalities (60%), and comparable to studies focusing on MCA aneurysm treatment with SAC (78.9–90.6%). In a previous experience including 184 Acomm aneurysms undergoing SAC, 86.9% showed complete occlusion and 13.1% recanalization during long-term surveillance; the overall procedural complication rate in the unruptured cohort was 5.7%. When considering treatment with the Woven EndoBridge (WEB) device, a series of 48 anterior communicating artery aneurysms reported


that complete occlusion was achieved in 62.5% of cases. In an early experience evaluating flow diverters for intracranial bifurcation aneurysm treatment, 97.3% of cases demonstrated no aneurysm filling at 18 months follow-up, with new permanent neurologic deficits occurring in 9.4% of cases. In a systematic review of flow diversion treatment of unruptured saccular anterior communicating artery aneurysms, complete occlusion was seen in 84.9% of cases, with an overall treatment-related complication rate of 8.6% (3.5% permanent complications).

Direct comparison among the techniques can be challenging due to variable aneurysm location, morphology, and flow dynamics. However, the ATLAS IDE cohort demonstrated high occlusion rates and an acceptable safety profile for distal and bifurcation anterior circulation aneurysms compared with historical data rates and an acceptable safety profile for distal and bifurcation anterior circulation aneurysms compared with historical data.

Additionally, at 1-year follow-up of the ATLAS IDE trial, 88.7% of ICA aneurysm patients were completely occluded, and 2.9% underwent retreatment. The safety endpoint was met by 1.4% of patients, corresponding to a single case of major ipsilateral stroke. Previous studies have described the feasibility of SAC for treating ICA aneurysms. In contemporary ICA aneurysm treatment, however, flow diverters have become one of the main strategies. PREMIER was the largest prospective trial evaluating the pipeline embolization device (PED) for treating small and medium-sized unruptured intracranial aneurysms (9%) located at the ICA. At 1-year follow-up, 81.9% with aneurysms had complete occlusion, retreatment rate was 2.9%, and safety endpoint was met by 2.1%. In a cohort comparing ophthalmic aneurysms treated with SAC (n=62) and PED (n=106), there was no significant difference in complete occlusion (76% vs 81%, p=0.52), retreatment rates (6.5% vs 0.9%, p=0.06), and neurologic complications (4.8% vs 9.4%, p=0.38) between the groups. In a similar study comparing differences in outcomes involving communicating ICA segment aneurysms, there were no significant differences in complete occlusion (70.6% vs 81%, p=0.45) and complications between SAC and PED. A propensity score matching was used to compare the outcomes of 309 patients with ICA aneurysms undergoing treatment with Atlas SAC and PED. There were no significant differences in the rates of aneurysm occlusion (89.9% vs 86.5%, p=0.486), total complications (5.6% vs 11.2%, p=0.177), or favorable functional outcome (96.6% vs 97.8%, p=1.0) between the Atlas and PED groups. The high occlusion rates in our study and the available literature suggest that SAC with the Atlas device remains an efficacious strategy for ICA aneurysm treatment.

LIMITATIONS

This analysis has some limitations that need to be acknowledged. There is a potential for selection bias since the study was non-randomized. This means that there could be other factors influencing the results that were not captured in the dataset. Heterogeneity within the groups may limit the evaluation of the primary intervention effect on primary outcomes between proximal and distal aneurysms, including location-specific effects. Loss of follow-up was noted in a subset of patients, which could potentially introduce uncertainty to the generalizability of our findings. However, it is reassuring to observe that the proportion of patients lost to follow-up was evenly distributed between the groups, which might mitigate some of the associated risks of bias. It is worth noting that challenges in securing complete angiographic follow-up are not uncommon in prospective studies of this nature. Despite these limitations, this study also had strengths. The study design included an independent central imaging core lab and an independent clinical event committee, which helped reduce bias and validate the discussion on approach options for anterior circulation aneurysm treatment.

CONCLUSIONS

Our study demonstrated no significant differences in effectiveness and safety outcomes between proximal ICA aneurysms compared with distal and bifurcation aneurysms in patients treated with the Neuroform Atlas Stent System. These findings reemphasize the Atlas stent as a safe and efficacious treatment modality for unruptured anterior circulation intracranial aneurysms. A trend towards higher complications was observed for more distal aneurysms. Larger studies are needed to assess this possible difference.

Author affiliations

1Lyerly Neurosurgery, Baptist Medical Center Jacksonville, Jacksonville, Florida, USA
2Neurosurgery, Cooper Hospital University Medical Center, Camden, New Jersey, USA
3Neurosurgery, Mercy Health Saint Vincent Medical Center, Toledo, Ohio, USA
4Neurology, University of Pittsburgh Medical Center Health System, Pittsburgh, Pennsylvania, USA
5Neurosurgery, University of Pittsburgh Medical Center Health System, Pittsburgh, Pennsylvania, USA
6Neurosurgery, WellStar Health System, Marietta, Georgia, USA
7Radiology Imaging Associates, Swedish Medical Center, Englewood, Colorado, USA
8Styker Neurovascular, Fremont, California, USA
9Radiology, University of California San Francisco, San Francisco, California, USA

Twitter Amin Aghaebrahim @dminajax and Donald Frei @donfreimd

Acknowledgements

The authors acknowledge Patricia Morgan and the Styker team for their assistance.

Collaborators

For the ATLAS Investigators: Lyerly Neurosurgery-Baptist (19) - Ricardo Hanel (PI), Eric Sauvageau (Sub-I), Amin Nima Aghaebrahim (Sub-I), Nancy Ekebo (CRC), Karen Bell (CRC), Lanaya Lewis (CRC); Mercy St. Vincent (18) - Osama Zaidat (PI), Eugene Lin (Sub-I), Tina M Steinhauser (CRC), Dee Tilley (CRC), Julie Goins-Whitmore (past CRC), Brandi Bresem (past CRC), Melissa A Thomas (past CRC); University of Pittsburgh (17) - Ashutosh Jadhav (PI and past Sub-I), Julie Gross (Sub-I), Lisa Baxendell (CRC), Patricia Feineigle (CRC), Vicki Gilchrist (CRC), Brian Jankowitz (past Sub-I and past PI), Andrew Ducruet (past Sub-I), David Panckowski (past Sub-I), Hazem Shirah (past Sub-I), Alhamza Al-Bayati (past Sub-I), Amin Aghaebrahim (past Sub-I), Tudor Jovin (past Sub-I), Greg Weiner (past Sub-I), Cynthia Kenmuri (past Sub-I), Prasanna Tadi (past Sub-I), Gregory Walker (past Sub-I), Kelsea Haibach (past Sub-I), Carolynl Graves (past CRC), Yvonne Cannon (past CRC), WellStar Research Institute (16) - Ahmad Khalih (PI), Rishi Gupta (past Sub-I), Marianne Bain (CRC), Laura Murphy (CRC), Andrew A Foster (past CRC), Tasha Futch (past CRC), Portia Thomas (past CRC); RIA Swedish (14) - Don Frei (current PI and past Sub-I), Richard Bellon (Sub-I), Benjamin Atchue (Sub-I), Ian Kaminsky (Sub-I), Lisa Koldis (CRC), Mark Talley (CRC), Tiffany Talley (CRC), Alex Edinger (CRC), David Loy (past Sub-I and past PI), Dan Huddle (past Sub-I), Michelle Lixin (past Sub-I), Brad Fasbinder (CRC), Alicia Drew (past CRC), Joanna Sneed (past Sub-I), Ashley Bittner (past Sub-I), Sarah Weiss (past Sub-I), Nancy Sadaoui (past Sub-I), Tufts Medical Center (12) - Adel Malek (PI), Emma Jost-Price (CRC), Keri Sullivan (CRC), Haley Huggins (past CRC), Lindsey Soll (past CRC), Sarah Gans (past CRC), Michelle Bettle (past CRC); Cleveland Clinic Foundation (10) - Gabor Toth (PI), Mark Bain (Sub-I), Peter Rasmussen (Sub-I), M Shazam Hussain (Sub-I), Nina Moore (Sub-I), Thomas Masaryk (Sub-I), Mohamed Elgably (Sub-I), Erin Bynum (CRC), Russell Cerejo (past Sub-I), Julian Hardman (past Sub-I), Seby John (past Sub-I), Andrew Bauer (past Sub-I), Erin Mayock (past CRC), Vikram Puvenna (past CRC), Jenny Poh-Chir Tsai (past Sub-I), SUNY Buffalo (9) - Adnan Siddiqui (PI), Elad Levy (Sub-I), Kenneth Snyder (Sub-I), Jason Davies (Sub-I), Mary Hartney (past CRC), Joanna Sadowski (CRC), Courtnie Drozdowski (past CRC), Heather Ross (past CRC), Linda Bokhagen (past CRC); Beth Israel Deaconess (7) - Ajith Thomas (PI), Christopher Ogivly (Sub-I), Patricia Baum (CRC); Virginia Commonwealth (7) - John Reavey-Cantwell (PI), Dennis Rivet (Co-PI), Charlotte Gilman (CRC); Cedars Sinai Medical Center (6) - Michael Alexander (PI), John Reavey (past Sub-I), Dennis Rivers (past Sub-I), Michelle Sizer (past Sub-I), Susan Kohn (past Sub-I), Michelle Bay (past Sub-I), Katelin Kelsey (past Sub-I), Tracy Taylor (past Sub-I), Sarah Young (past Sub-I), Ramin Jafri (past Sub-I), Nasser Ghassemi (past Sub-I), Randall Hodge (past Sub-I), Michelle Lixin (past Sub-I), Brad Fasbinder (CRC), Alicia Drew (past CRC), Joanna Sneed (past Sub-I), Ashley Bittner (past Sub-I), Sarah Weiss (past Sub-I), Nancy Sadaoui (past Sub-I), Tufts Medical Center (12) - Adel Malek (PI), Emma Jost-Price (CRC), Keri Sullivan (CRC), Haley Huggins (past CRC), Lindsey Soll (past CRC), Sarah Gans (past Sub-I), Michelle Bettle (past CRC); Cleveland Clinic Foundation (10) - Gabor Toth (PI), Mark Bain (Sub-I), Peter Rasmussen (Sub-I), M Shazam Hussain (Sub-I), Nina Moore (Sub-I), Thomas Masaryk (Sub-I), Mohamed Elgably (Sub-I), Erin Bynum (CRC), Russell Cerejo (past Sub-I), Julian Hardman (past Sub-I), Seby John (past Sub-I), Andrew Bauer (past Sub-I), Erin Mayock (past CRC), Vikram Puvenna (past CRC), Jenny Poh-Chir Tsai (past Sub-I), SUNY Buffalo (9) - Adnan Siddiqui (PI), Elad Levy (Sub-I), Kenneth Snyder (Sub-I), Jason Davies (Sub-I), Mary Hartney (past CRC), Joanna Sadowski (CRC), Courtnie Drozdowski (past CRC), Heather Ross (past CRC), Linda Bokhagen (past CRC); Beth Israel Deaconess (7) - Ajith Thomas (PI), Christopher Ogivly (Sub-I), Patricia Baum (CRC); Virginia Commonwealth (7) - John Reavey-Cantwell (PI), Dennis Rivet (Co-PI), Charlotte Gilman (CRC); Cedars Sinai Medical Center (6) - Michael Alexander (PI), Franklin Moser (past Sub-I), Marcel Maya (Sub-I), Michael Schiraldi (Sub-I), Vicki Manoukian, MA (CRC), Paula Eboi (past Sub-I); Johns Hopkins University (6) - Justin Caplan (past PI), Bowen Jiang (past Sub-I), Matthew Bender (Sub-I), Ellen Sheehan (CRC), Jessica Wollett (CRC),
Hemorrhagic stroke

Geoffrey Colby (past PI), Lauren Disce (past CRC), Anna Bugaeva (past CRC), Barbara Michniewicz (past CRC), Thomas Hemmingson (past CRC), Christiana Care Health Services (5) - Sudhakar Satti (PI), Thinesh Sivapatham (Sub-PI), Rob Zent (CRC), Ann Marie Le Noir (CRC); Hospital of the University of PA (5) - David Kung (current PI and past Sub-PI), Bryan Pukenas (Sub-PI), Robert Hurst (Sub-PI), Timothy Prior (CRC), Whitney Sarchiopane (CRC), Yelena Gorelik (past CRC), Francis Quattrone (past CRC), Michelle J. Smith (past PI); Univ of Massachusetts (4) - Ajit Puri (PI), Francesco Massari (Sub-PI), Mary Howk (CRC), David Rex (past PI and Sub-PI), Kimberly Ty (past CRC), Jen Donham (past CRC), Wen Li (past CRC); University of Kentucky (4) - Justin Fraser (current PI and past Sub-PI), Stephen Grupke (Sub-PI), Jennifer Isaac (CRC), Abdullaher Alahjai (past PI); Carolina Rodgers (past CRC); Linda Joyce McCown (past CRC); Harborview Medical Center (3) - Abdulnasser Alhajeri (past PI), Caroline Rodgers (past Sub-PI), John Dao (past CRC), Francisco Acosta (past CRC); Harborview Medical Center (3) - Michelle Raymond (CRC), Sushant Kale (past CRC), Michelle Prystash (CRC), Vivian Escamilla (CRC); Cleveland Clinic (3) - Geoff Colby (past PI), Lauren Dise (past CRC), Anna Bugaeva (past CRC), Barbara McKeel (past CRC).

Ethics approval
This study involves human participants and was approved by

Contributors
RAH and GMC drafted the initial manuscript. All the authors were involved and made substantial contributions to the conception or design of the work, or the acquisition, analysis, or interpretation of the data; revising the manuscript critically for important intellectual content; final approval of the version published; and agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. RAH is responsible for the overall content as the guarantor.

Funding
The ATLAS trial (Safety and Effectiveness of the Treatment of Wide Neck, Saccular Intracranial Aneurysms with the Neuroform Atlas Stent System) was funded by Stryker Neurovascular.

Competing interests
RAH is a consultant for Medtronic, Stryker, Cereneovus, Microvention, Balt, Pharoc, Rapid Medical and Q’Apel, Imperative Care, Pharoc, and Rapid Medical. He is on the advisory board for MIVI, elum, Three Rivers, Shape Medical, and Corindus. He is in receipt of unrestricted research grants from the National Institutes of Health (NIH), Interline Endowment, Microvention, Stryker, Cerenovus, and Balt. He is on the investigator/stockholder for Intero Corp, Cerebraflow, Endostream, Three Rivers Medical Inc, Scientia, Rist, BlinkTBI, and Corindus. BTI is a consultant for Stryker and a consultant/proctor for Medtronic. ES reports a speaker’s agreement with Stryker. BG is a consultant for Medtronic, Microvention, and Stryker. RGG is a consultant and receives personal fees from Cereneovus. DF reports consultant/speakers bureau for Stryker, Siemens, Penumbra, and Scientia; and serves on the SNIS board of directors. LLP is a Principal Biostatistician employed at Stryker Neurovascular and holds stock in Stryker. SWH reports core lab services for Stryker, Route 92; is an Imperative Care consultant; is a stockholder for Filter and ThrombX; and serves on the SNIS board of directors. O2Z reports research grants from Stryker, Medtronic, Cereneovus, Penumbra, and Genentech; he is a consultant and speaker for Cereneovus, Stryker, Penumbra, and Medtronic; data safety monitoring board for Premier; has an ownership interest in Galaxy Therapeutics Inc.; and serves on SVIN committees. The other authors report no conflicts of interest.

Patient consent for publication
Not applicable.

Ethics approval
This study involves human participants and was approved by

REFERENCES


